News

With products ranging from cardboard boxes to new drugs, these companies are all on track to double their earnings.

In the high-stakes world of big pharma, the slower-growing giant now commands the higher price, forcing investors to decide what that premium is truly buying.

A healthcare titan is in a full sprint, but a recent stumble has investors asking if the best part of the race is already over.

Eli Lilly and Nvidia both just posted stunning quarters riding two of the biggest secular waves in markets today, but a $10,000 bet can only tilt one way. Which secular story holds the sharper edge heading into 2026?

Eli Lilly just crossed the trillion-dollar threshold on the back of a GLP-1 empire growing at nearly 50% annually, but a recent pullback and rising risks are forcing investors to decide whether this pharmaceutical giant still has meaningful upside left.

ABBV's Skyrizi and Rinvoq drives immunology growth, while new indications, acquisitions and partnerships build its next wave.

AbbVie (ABBV) has returned 23.3% over the past year, ahead of the S&P 500's (SPY) 18.5%, and the business behind that return has changed shape. Humira, the drug whose decline management once explained, took one sentence on the July 2026 earnings call. What that sentence no longer contains is the part a holder should look at.

This company aims to serve a market heading toward $100 billion.

Eli Lilly, Palo Alto Networks and Texas Instruments benefit from strong demand and strategic moves, while Stratus advances asset sales.

Eli Lilly, Palo Alto Networks and Texas Instruments benefit from strong demand, strategic moves and growth prospects despite key risks.

Eli Lilly (LLY) stock has gained about 56% over the past year, moving from $722.65 to $1,123.91. Before that run the company was doing something strange. It was deliberately selling less medicine than people wanted to buy, and it kept saying so out loud.

Growth stocks have been down for months, but there are signals that it’s time for them to move higher again.

On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli Lilly and Company (NYSE:LLY) rather than chase Johnson & Johnson (NYSE:JNJ) or Cardinal Health (NYSE:CAH). Mad Money host Jim Cramer said: Well, I’ll tell you… I think it’s always good to look at Lilly as a stock […]

Kura Oncology, Inc. (NASDAQ:KURA) on Wednesday announced $50 million financing tied to advancing its menin-inhibition strategy. Launches Caspian Therapeutics With $50 Million Financing Kura said it is launching Caspian Therapeutics alongside a $50 million financing led by BVF Partners, with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Co. (NYSE:LLY), Kura Oncology, members of Kura’s leadership team, and other investors. The stated goal is to advance the company’s work in meni

PFE's non-COVID growth, oncology pipeline and cost cuts offer a path forward as COVID sales fall and patent losses loom.

Caspian Therapeutics aims to develop menin inhibitors, which have proven effective against leukemia, for diabetes and other cardiometabolic conditions.

Hint: It's a good idea to buy the stock today.

The latest trading day saw Eli Lilly (LLY) settling at $1, representing a -2.21% change from its previous close.

US non-residential construction is approaching a reacceleration, driven by semiconductor and pharmac

Shares of Amgen were recently down more than 9%, putting the biotechnology company on pace for its largest decrease since October 2000. The decline came after Novartis announced a failure of its heart disease drug, pelacarsen, to reduce the risk of cardiovascular events compared with a placebo. The failure, which sent U.S.-traded Novartis shares down 14%, also cast doubt on similar drugs, including Amgen’s investigational treatment olpasiran.

Shifting emphasis from symptoms to biomarkers has bolstered sector confidence in emerging CNS therapies.

Novo announced successful results from a Phase 3 study of its injectable GLP1 drug Wegovy in obese children aged six to 12.

AbbVie (ABBV) trades at $256.46, roughly 96% of its 52-week high, after returning 24.1% over the past twelve months against 19.7% for the S&P 500. That price buys a business where about a third of guided 2026 revenue comes from one drug. The market reads that concentration as strength. It is worth reading it the other way too.

Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same morning.

Shares of Novo Nordisk are trading 66% below their 2024 high, but is that enough to call them cheap? Maybe.

Merck (MRK) has returned about 85% over the past year and at about $150 trades roughly 4% below its 52-week high. A year ago, management spent earnings calls managing fallout from a steep drop in GARDASIL sales. That problem has left the lead. What management opens with instead is a much larger claim, and it settles years from now.

Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday, leading to a widespread drop.

According to the average brokerage recommendation (ABR), one should invest in Lilly (LLY). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

NVO's semaglutide cuts BMI in children with obesity in phase III study, with 40.4% no longer classified as having obesity after 68 weeks.

Pelacarsen lowered Lp(a) levels in more than 8,000 patients but did not reduce the risk of heart attacks, strokes, or cardiovascular death